TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, METHODS FOR THEIR PREPARING (VARIANTS), PHARMACEUTICAL COMPOSITION Russian patent published in 2004 - IPC

FIELD: organic chemistry, heterocyclic compounds, chemical technology, pharmacy. SUBSTANCE: invention relates to new triazolo[4,5-d]pyrimidine compounds of the general formula (I) or their pharmaceutically acceptable salts that elicit effect of P_2T-antagonists, in particular, show activity inhibiting platelets aggregation. Invention relates also to methods for preparing compounds of the formula (I) and pharmaceutical composition. In compounds of the general formula (I) R¹ represents C_1-6-alkyl, C_2-6- alkenyl, C_2-6-alkynyl, C_3-8-cycloalkyl or phenyl group wherein each group is substituted optionally with one or some substituents taken among halogen atom, OR⁸, NR⁹R¹⁰, SR¹¹ or C_1-6-alkyl (that in turn is substituted optionally with one or some halogen atoms); R² represents C_1-8-alkyl optionally substituted with one or some substituents taken among halogen atom, OR⁸, NR⁹R¹⁰, SR¹¹, C_3-8-cycloalkyl, aryl (optionally substituted with one or some C_1-6-alkyl groups and/or halogen atoms) or C_1-6-alkyl; or R² represents C_3-8-cycloalkyl group optionally substituted with one or some substituents taken among halogen atom, OR⁸, NR⁹R¹⁰, SR¹¹, C_1-6-alkyl or phenyl; two latter groups are substituted optionally with one or some substituents taken among halogen atom, NO₂, C(O)R⁸, OR⁸, SR¹¹, NR¹²R¹³, condensed 5- or 6- membered saturated ring comprising one or two oxygen atoms, phenyl or C_1-6-alkyl; two latter groups are substituted optionally with OR⁸, NR⁹R¹⁰ or one or some halogen atoms; one of R³ and R⁴ represents hydroxy-group and another represents hydrogen atom, hydroxy-group or NR⁹R¹⁰; R represents group (CR⁵R⁶)_mOR⁷ wherein m = 0 or 1; R⁵ and R⁶ represent independently hydrogen atom, C_1-6-alkyl or phenyl; two latter groups are substituted optionally with halogen atom; R⁷ represents hydrogen atom, C_1-6-alkyl or wherein R⁵ and R⁶ are determined above; n = 1-3; R¹⁴ represents COOH, OR¹⁵, NR¹⁶R¹⁷ or CONR¹⁶R¹⁷; or R represents C_1-4-alkyl or C_2-4-alkenyl group being each of them is substituted with one or some groups taken among =S, =O, =NR²⁰ or OR²¹ and substituted optionally with one or some groups taken among halogen atom, C_1-4-alkyl, phenyl, SR²¹, NO₂ or NR²²R²³ (wherein R²¹, R²² and R²³ represent independently hydrogen atom, C_1-4-alkyl or phenyl; R²⁰ represents OR²⁴ or NR²⁵R²⁶ wherein R²⁴ represents hydrogen atom, C_1-4-alkyl or phenyl; R²⁵ and R²⁶ represent independently hydrogen atom, C_1-4-alkyl, aryl, C_1-6-acyl, arylsulfonyl or arylcarbonyl); R⁸ represents hydrogen atom, C_1-6- alkyl optionally substituted with halogen atom; or R⁸ represents phenyl optionally substituted with one or some substituents taken among halogen atom, NO₂, C(O)⁶, OR⁶, SR⁹, NR¹⁰R¹¹; R⁹, R¹⁰, R¹¹ represent independently hydrogen atom or C_1-6- alkyl; R¹² and R¹³ represent independently hydrogen atom, C_1-6-alkyl, acyl, alkylsulfonyl optionally substituted with halogen atom or phenylsulfonyl optionally substituted with C_1-4-alkyl; R¹⁵, R¹⁶, R¹⁷ represent independently hydrogen atom or C_1-6-alkyl. EFFECT: improved preparing method, valuable medicinal properties of compounds. 20 cl, 1 tbl, 118 ex